302 related articles for article (PubMed ID: 31602572)
1. Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Lee YH; Song GG
Clin Drug Investig; 2020 Jan; 40(1):65-72. PubMed ID: 31602572
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Int J Rheum Dis; 2020 Jul; 23(7):868-875. PubMed ID: 32483919
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2020 Jun; 58(6):293-298. PubMed ID: 32301699
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis : A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Z Rheumatol; 2018 May; 77(4):335-342. PubMed ID: 28097393
[TBL] [Abstract][Full Text] [Related]
6. Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
Genovese MC; Greenwald M; Codding C; Zubrzycka-Sienkiewicz A; Kivitz AJ; Wang A; Shay K; Wang X; Garg JP; Cardiel MH
Arthritis Rheumatol; 2017 May; 69(5):932-942. PubMed ID: 28118538
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritis : A Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Z Rheumatol; 2018 Jun; 77(5):421-428. PubMed ID: 28324148
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis
.
Bae SC; Lee YH
Int J Clin Pharmacol Ther; 2019 Apr; 57(4):188-196. PubMed ID: 30574867
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC; Song GG
Rheumatol Int; 2015 Dec; 35(12):1965-74. PubMed ID: 25994093
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Int J Rheum Dis; 2018 May; 21(5):922-929. PubMed ID: 29671942
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Song GG; Lee YH
Z Rheumatol; 2020 Feb; 79(1):103-111. PubMed ID: 30725185
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.
Takeuchi T; Tanaka Y; Iwasaki M; Ishikura H; Saeki S; Kaneko Y
Ann Rheum Dis; 2016 Jun; 75(6):1057-64. PubMed ID: 26672064
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of olokizumab at different dosages in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Z Rheumatol; 2024 Feb; 83(Suppl 1):107-114. PubMed ID: 37266677
[TBL] [Abstract][Full Text] [Related]
16. Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.
Kivitz AJ; Gutierrez-Ureña SR; Poiley J; Genovese MC; Kristy R; Shay K; Wang X; Garg JP; Zubrzycka-Sienkiewicz A
Arthritis Rheumatol; 2017 Apr; 69(4):709-719. PubMed ID: 27748083
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Clin Rheumatol; 2018 May; 37(5):1199-1205. PubMed ID: 29392511
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Iwasaki M; Katayama K; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Shiomi T; Yamada E; van der Heijde D
Ann Rheum Dis; 2019 Oct; 78(10):1305-1319. PubMed ID: 31350269
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Z Rheumatol; 2019 Aug; 78(6):559-567. PubMed ID: 30191390
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and tolerability of monotherapy with leflunomide or tacrolimus for the treatment of rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Clin Rheumatol; 2018 Feb; 37(2):323-330. PubMed ID: 28967035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
